https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-03-28 / Biomedicines 2024 Mar;12(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-03-28 / Biomedicines 2024 Mar;12(4)2024-03-28 00:00:002024-04-30 08:35:31Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2023-11-07 17:20:492024-01-18 12:04:25Neue IOZK Veröffentlichung zum Thema Liquid Biopsy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-19 / Methods Cell Biol 2024;183:51-113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-19 / Methods Cell Biol 2024;183:51-1132023-10-19 00:00:002024-04-20 10:47:17Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-06-23 / Biomedicines 2023 Jun;11(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2020/11/IOZK_team_van-gool_175828-ret.jpg
518
690
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2023-01-23 16:08:352023-01-25 16:42:45Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-10-27 / Int J Mol Sci 2022 Oct;23(21)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-10-27 / Int J Mol Sci 2022 Oct;23(21)2022-10-27 00:00:002023-01-31 13:01:45Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-28 / Biomedicines 2022 Feb;10(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002024-11-18 14:56:13Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-28 / Biomedicines 2022 Feb;10(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002022-06-27 12:27:29Poster presentation at the International Symposium on Pediatric Neuro-Oncology
